Compare Amphastar Pharmaceuticals Inc (AMPH) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Lowe`s Companies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Lowe`s Companies Inc trades at $212.03 (market cap $118.66B). The key difference: Lowe`s Companies Inc is far larger — about 143.6× Amphastar Pharmaceuticals Inc's market cap, and Lowe`s Companies Inc pays a 2.36% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | LOW | |
|---|---|---|
Market Cap | $826.08M | $118.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $287.39 |
52-Week Low | $16.87 | $206.62 |
Enterprise Value | $1.22B | $160.42B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Lowe's Companies (LOW) trades at $211.63, down 0.64% on the day, with a bearish technical signal from moving averages. The company maintains solid fundamentals with a P/E of 17.89 and net income margin of 7.51%, having beaten earnings estimates for three consecutive quarters. Revenue declined to $83.67 billion in 2025 but shows stabilization with 2026 projections of $88.4 billion. Analyst consensus remains strongly bullish with a $260.88 price target, representing 23% upside potential from current levels.
LOW presents a compelling value opportunity with strong dividend growth and consistent earnings performance, though near-term headwinds include housing market sensitivity and competitive pressures. The stock's current valuation discount to analyst targets and improving cash flow trends support a positive medium-term outlook, balanced by technical weakness and macroeconomic uncertainties affecting the home improvement sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
